NASDAQ:ONCE - Spark Therapeutics Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00 %
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$113.57
+0.30 (1.20%)
Get New Spark Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ONCE and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ONCE

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for Spark Therapeutics in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $113.57.

This chart shows the closing price for ONCE for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is N/A

The current consensus among 0 contributing investment analysts is to n/a stock in Spark Therapeutics. This rating has held steady since November 2020, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 0 sell ratings
5/2/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 0 sell ratings
7/31/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
10/29/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/27/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/27/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/26/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/24/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/24/2021

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
12/17/2019William BlairReiterated RatingHoldLow
8/12/2019MizuhoReiterated RatingHold$114.50High
3/25/2019BarclaysDowngradeOverweight ➝ Equal Weight$74.00 ➝ $115.00Low
3/7/2019William BlairDowngradeOutperform ➝ Market PerformLow
2/27/2019Stifel NicolausDowngradeBuy ➝ Hold$65.00 ➝ $114.50Low
2/26/2019Jefferies Financial GroupDowngradeBuy ➝ Hold$85.00 ➝ $114.50Low
2/26/2019Sanford C. BernsteinDowngradeOutperform ➝ Market Perform$113.48Low
2/26/2019BMO Capital MarketsBoost Price TargetMarket Perform ➝ Market Perform$46.00 ➝ $114.50Low
2/26/2019William BlairInitiated CoverageBuyLow
2/25/2019Raymond JamesDowngradeStrong-Buy ➝ Market PerformLow
2/25/2019SunTrust BanksDowngradeBuy ➝ HoldN/A
2/25/2019MizuhoDowngradeBuy ➝ NeutralN/A
2/25/2019Cantor FitzgeraldDowngradeOverweight ➝ Neutral$80.00 ➝ $114.50N/A
2/19/2019Credit Suisse GroupReiterated RatingHold$47.00Low
2/19/2019William BlairReiterated RatingBuyLow
2/17/2019Cantor FitzgeraldReiterated RatingBuy$80.00High
2/8/2019Credit Suisse GroupReiterated RatingHold$44.00Low
1/10/2019Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$103.00 ➝ $80.00Medium
1/7/2019Credit Suisse GroupReiterated RatingHold$44.00Medium
12/3/2018Cantor FitzgeraldSet Price TargetBuy$103.00Medium
12/3/2018William BlairReiterated RatingBuyMedium
11/26/2018Raymond JamesReiterated RatingBuyMedium
11/16/2018Credit Suisse GroupUpgradeUnderperform ➝ Neutral$48.00 ➝ $44.00Low
11/7/2018MizuhoLower Price TargetBuy$62.00Medium
11/7/2018BMO Capital MarketsLower Price TargetMarket Perform$48.00High
11/7/2018B. RileyUpgradeNeutral ➝ Buy$68.00 ➝ $71.00High
11/7/2018WedbushUpgradeUnderperform ➝ Neutral$40.00 ➝ $40.00High
11/7/2018JPMorgan Chase & Co.Reiterated RatingHold$60.00High
11/6/2018William BlairReiterated RatingBuyMedium
11/6/2018Cantor FitzgeraldSet Price TargetBuy$103.00High
10/9/2018GuggenheimInitiated CoverageBuy ➝ Buy$70.00High
10/8/2018Cantor FitzgeraldSet Price TargetBuy$103.00Low
10/1/2018Cantor FitzgeraldSet Price TargetBuy$103.00Medium
9/21/2018Raymond JamesReiterated RatingBuyHigh
9/21/2018William BlairReiterated RatingBuyHigh
9/21/2018Cantor FitzgeraldSet Price TargetBuy$103.00High
8/8/2018SunTrust BanksLower Price TargetBuy$61.00Low
8/8/2018UBS GroupLower Price TargetNeutral ➝ Neutral$80.00 ➝ $53.00Medium
8/8/2018BarclaysLower Price TargetOverweight ➝ Overweight$85.00 ➝ $77.00Medium
8/8/2018Raymond JamesSet Price TargetBuy$82.00Low
8/8/2018Royal Bank of CanadaLower Price TargetSector Perform$64.00High
8/8/2018Stifel NicolausLower Price TargetBuy ➝ Buy$76.00 ➝ $68.00Medium
8/8/2018Chardan CapitalBoost Price TargetNeutral$60.00 ➝ $85.00Medium
8/8/2018MizuhoReiterated RatingBuy$77.00High
8/7/2018BMO Capital MarketsDowngradeOutperform ➝ Market Perform$60.00High
8/7/2018Credit Suisse GroupReiterated RatingOutperform ➝ Underperform$98.00 ➝ $98.00High
8/7/2018SVB LeerinkReiterated RatingMarket Perform$74.00 ➝ $55.00Medium
8/7/2018CitigroupUpgradeNeutral ➝ BuyHigh
8/7/2018Cantor FitzgeraldReiterated RatingBuy$103.00High
7/19/2018Royal Bank of CanadaDowngradeOutperform ➝ Sector Perform$100.00High
7/16/2018Cantor FitzgeraldSet Price TargetBuy$103.00Low
7/9/2018Credit Suisse GroupBoost Price TargetOutperform ➝ Outperform$75.00 ➝ $98.00Low
6/28/2018B. RileyInitiated CoverageNeutral$74.00Low
6/25/2018BMO Capital MarketsBoost Price TargetOutperform ➝ Outperform$78.00 ➝ $98.00High
5/23/2018Raymond JamesReiterated RatingBuyHigh
5/22/2018Cantor FitzgeraldSet Price TargetBuy$103.00High
5/9/2018WedbushReiterated RatingUnderperform$40.00Low
5/9/2018BMO Capital MarketsSet Price TargetOutperform ➝ Buy$64.00 ➝ $78.00High
5/9/2018Stifel NicolausBoost Price TargetBuy ➝ Buy$64.00 ➝ $76.00High
5/9/2018Royal Bank of CanadaBoost Price TargetOutperform$75.00High
5/9/2018BarclaysReiterated RatingPositive ➝ Overweight$64.00 ➝ $85.00High
5/8/2018CowenReiterated RatingBuy$85.00High
5/8/2018MizuhoReiterated RatingBuy$91.00High
5/8/2018Cantor FitzgeraldSet Price TargetBuy$103.00Medium
5/7/2018SVB LeerinkReiterated RatingMarket Perform$55.00High
5/1/2018JPMorgan Chase & Co.Boost Price TargetNeutral ➝ Neutral$60.00 ➝ $63.00Low
5/1/2018CitigroupInitiated CoverageNeutral ➝ Neutral$85.00Medium
5/1/2018MizuhoReiterated RatingBuy$91.00Medium
4/30/2018Cantor FitzgeraldReiterated RatingOverweight ➝ Buy$100.00 ➝ $103.00High
4/23/2018Chardan CapitalDowngradeBuy ➝ Neutral$80.00 ➝ $85.00High
4/19/2018William BlairReiterated RatingBuyLow
3/29/2018MizuhoSet Price TargetBuy$79.00Low
3/8/2018Credit Suisse GroupReiterated RatingOutperform ➝ Outperform$61.00 ➝ $75.00Medium
2/21/2018Raymond JamesSet Price TargetBuy$66.00High
2/21/2018BMO Capital MarketsSet Price TargetOutperform ➝ Buy$66.00 ➝ $64.00Medium
2/21/2018Sanford C. BernsteinReiterated RatingBuy$71.00 ➝ $60.00Low
2/21/2018Stifel NicolausReiterated RatingBuy ➝ Buy$73.00 ➝ $64.00Low
2/21/2018MizuhoReiterated RatingBuy$79.00Low
2/20/2018Cantor FitzgeraldSet Price TargetBuy$100.00Low
2/14/2018JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral$62.00 ➝ $60.00Low
2/12/2018MizuhoInitiated CoverageBuy ➝ Buy$79.00Low
2/8/2018Royal Bank of CanadaReiterated RatingOutperform ➝ Outperform$65.00High
1/25/2018BMO Capital MarketsBoost Price TargetOutperform ➝ Outperform$64.00 ➝ $66.00Medium
1/25/2018WedbushBoost Price TargetUnderperform ➝ Positive$35.00 ➝ $40.00Medium
1/24/2018Cantor FitzgeraldReiterated RatingBuy$105.00Medium
1/23/2018BarclaysReiterated RatingOverweight ➝ Buy$61.00 ➝ $64.00Low
1/17/2018Credit Suisse GroupInitiated CoverageOutperform ➝ Outperform$61.00Medium
1/16/2018WedbushDowngradeNeutral ➝ Underperform$50.00 ➝ $35.00Medium
1/4/2018SunTrust BanksBoost Price TargetBuy$113.00High
1/3/2018Raymond JamesSet Price TargetBuy$66.00High
1/3/2018Cantor FitzgeraldSet Price TargetBuy$105.00High
1/2/2018BMO Capital MarketsSet Price TargetBuy$67.00High
12/19/2017Raymond JamesReiterated RatingBuyHigh
12/19/2017Cantor FitzgeraldSet Price TargetBuy$105.00Low
12/14/2017The Goldman Sachs GroupDowngradeBuy ➝ Neutral$106.00 ➝ $58.00Low
12/13/2017BarclaysReiterated RatingBuy$54.00Low
12/13/2017Sanford C. BernsteinSet Price TargetBuy$90.00 ➝ $71.00Medium
12/12/2017WedbushUpgradeUnderperform ➝ Neutral$65.00 ➝ $50.00Medium
12/12/2017Chardan CapitalLower Price TargetBuy ➝ Buy$100.00 ➝ $60.00High
12/12/2017BMO Capital MarketsSet Price TargetBuy$73.00High
12/12/2017SVB LeerinkDowngradeOutperform ➝ Market Perform$49.00High
12/12/2017UBS GroupDowngradeBuy ➝ Neutral$92.00 ➝ $51.00High
12/11/2017Cantor FitzgeraldSet Price TargetBuy$105.00High
12/7/2017Raymond JamesReiterated RatingBuy$75.00High
11/15/2017BMO Capital MarketsReiterated RatingBuy$101.00N/A
11/8/2017Royal Bank of CanadaLower Price TargetOutperform$100.00 ➝ $98.00N/A
10/25/2017Royal Bank of CanadaReiterated RatingBuyN/A
10/16/2017SunTrust BanksSet Price TargetBuy$101.00N/A
10/13/2017BarclaysBoost Price TargetOverweight$104.00 ➝ $107.00N/A
10/13/2017Cantor FitzgeraldLower Price TargetBuy$105.00 ➝ $94.00N/A
10/13/2017Stifel NicolausReiterated RatingBuy ➝ Buy$92.00 ➝ $101.00N/A
10/13/2017BMO Capital MarketsReiterated RatingOutperform$89.00 ➝ $101.00N/A
10/13/2017Chardan CapitalReiterated RatingBuy$100.00N/A
10/12/2017Raymond JamesInitiated CoverageOutperform ➝ Outperform$96.00N/A
10/10/2017BMO Capital MarketsSet Price TargetBuy$89.00N/A
10/10/2017CowenReiterated RatingBuy$95.00N/A
10/10/2017Jefferies Financial GroupReiterated RatingBuy$95.00N/A
10/10/2017Cantor FitzgeraldReiterated RatingBuy ➝ Buy$94.00 ➝ $105.00N/A
10/6/2017The Goldman Sachs GroupReiterated RatingBuy ➝ Buy$111.00N/A
9/25/2017SunTrust BanksReiterated RatingBuy$85.00 ➝ $95.00Medium
9/14/2017Royal Bank of CanadaInitiated CoverageOutperform ➝ Outperform$100.00Medium
9/6/2017BarclaysInitiated CoverageOverweight$104.00High
8/25/2017Cantor FitzgeraldReiterated RatingBuyLow
8/16/2017Evercore ISIInitiated CoverageIn ➝ In-Line$83.00High
8/8/2017Chardan CapitalUpgradeNeutral ➝ Buy$60.00 ➝ $100.00Low
8/3/2017Stifel NicolausReiterated RatingBuy$77.00 ➝ $92.00Low
8/3/2017CowenReiterated RatingOutperform$75.00 ➝ $95.00Low
8/3/2017Jefferies Financial GroupReiterated RatingBuy$85.00 ➝ $95.00High
8/3/2017BMO Capital MarketsReiterated RatingOutperform$69.00 ➝ $89.00High
8/3/2017UBS GroupReiterated RatingBuy$70.00 ➝ $92.00High
8/2/2017BMO Capital MarketsBoost Price TargetOutperform$69.00 ➝ $89.00Low
8/2/2017Chardan CapitalUpgradeNeutral ➝ Buy$60.00 ➝ $100.00Low
7/27/2017Sanford C. BernsteinInitiated CoverageOutperform$87.00Medium
7/24/2017Jefferies Financial GroupReiterated RatingBuy$85.00High
7/24/2017Chardan CapitalReiterated RatingHold ➝ NeutralHigh
7/17/2017Cantor FitzgeraldSet Price TargetBuy$94.00Medium
7/10/2017Jefferies Financial GroupInitiated CoverageBuy ➝ Buy$85.00Low
6/28/2017William BlairInitiated CoverageOutperform ➝ OutperformHigh
5/10/2017WedbushReiterated RatingUnderperform$28.00Medium
5/9/2017Cantor FitzgeraldSet Price TargetBuy$94.00Medium
4/26/2017Jefferies Financial GroupReiterated RatingHold$59.00Low
4/10/2017Stifel NicolausReiterated RatingBuy$76.00Low
4/7/2017BMO Capital MarketsReiterated RatingOutperform$69.00Low
3/29/2017UBS GroupInitiated CoverageBuy ➝ Buy$70.00N/A
2/23/2017Cantor FitzgeraldReiterated RatingBuy$94.00N/A
2/23/2017Stifel NicolausBoost Price TargetBuy$73.00 ➝ $76.00N/A
2/22/2017Jefferies Financial GroupSet Price TargetHold$59.00N/A
2/22/2017CowenSet Price TargetBuy$75.00N/A
2/22/2017JPMorgan Chase & Co.Set Price TargetBuy$82.00N/A
2/22/2017WedbushReiterated RatingUnderperform$28.00N/A
2/9/2017SVB LeerinkInitiated CoverageOutperform ➝ Outperform$85.00N/A
1/10/2017Jefferies Financial GroupReiterated RatingHold$57.00N/A
12/20/2016BMO Capital MarketsInitiated CoverageOutperform$69.00N/A
12/6/2016Jefferies Financial GroupReiterated RatingHold$47.00N/A
12/6/2016Chardan CapitalReiterated RatingNeutralN/A
12/5/2016WedbushReiterated RatingUnderperform$28.00N/A
11/7/2016Chardan CapitalReiterated RatingNeutral$55.00 ➝ $47.50N/A
11/7/2016JPMorgan Chase & Co.Reiterated RatingBuyN/A
11/4/2016Cantor FitzgeraldReiterated RatingBuy$94.00N/A
(Data available from 10/24/2016 forward)

News Sentiment Rating

0.35 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/28/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/27/2021
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/27/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/26/2021
  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/26/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/25/2021
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/24/2021
  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/24/2021

Current Sentiment

  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.
Spark Therapeutics logo
Spark Therapeutics, Inc. focuses on the development of gene therapy products for patients suffering from debilitating genetic diseases. Its products include LUXTURNA (voretigene neparvovec) for the treatment of patients with confirmed biallelic RPE65 mutation-associated retinal dystrophy and viable retinal cells. The company's gene therapy product candidates comprise SPK-8011 and SPK-8016 for hemophilia; SPK-7001 for choroideremia; and SPK-9001 for hemophilia B. It is also developing other liver-directed gene therapies, including SPK-3006 for Pompe disease; and neurodegenerative disease product candidates to address Huntington's disease and others, as well as TPP1 deficiency, which is a form of Batten disease. The company's preclinical programs targets inherited retinal diseases, including Stargardt's disease. The company has collaboration agreement with Pfizer, Inc. for the development and commercialization of SPK-FIX product candidates in its gene therapy program for the treatment of hemophilia B. It also has licensing and commercialization agreement with Novartis to develop and commercialize voretigene neparvovec outside the United States. Spark Therapeutics, Inc. was founded in 2013 and is headquartered in Philadelphia, Pennsylvania.
Read More

Today's Range

Now: $113.57
Low: $113.57
High: $113.57

50 Day Range

MA: $113.43
Low: $110.05
High: $113.57

52 Week Range

Now: $113.57
Low: $34.53
High: $114.20

Volume

8,720 shs

Average Volume

891,560 shs

Market Capitalization

$4.38 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.05

Frequently Asked Questions

What sell-side analysts currently cover shares of Spark Therapeutics?

The following Wall Street sell-side analysts have issued research reports on Spark Therapeutics in the last twelve months:
View the latest analyst ratings for ONCE.

What is the current price target for Spark Therapeutics?

0 Wall Street analysts have set twelve-month price targets for Spark Therapeutics in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Spark Therapeutics in the next year.
View the latest price targets for ONCE.

What is the current consensus analyst rating for Spark Therapeutics?

Spark Therapeutics currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for ONCE.

What other companies compete with Spark Therapeutics?

How do I contact Spark Therapeutics' investor relations team?

Spark Therapeutics' physical mailing address is 3737 MARKET STREET SUITE 1300, PHILADELPHIA PA, 19104. The biotechnology company's listed phone number is 888-772-7560 and its investor relations email address is [email protected] The official website for Spark Therapeutics is www.sparktx.com.